background Bevacizumab (Avastin®) is a recombinant humanized monoclonal antibody that binds to and neutralizes the biological activity of vascular endothelial growth factor-A (VEGF-A), thereby preventing the activation of the VEGF receptor and ultimately angiogenesis [1] . Bevacizumab may improve the delivery of chemotherapy by altering tumor vasculature and decreasing the elevated interstitial pressure in the tumors [2, 3] . Significant activity of bevacizumab in cancer was first appreciated in patients with colorectal cancer. An addition of bevacizumab to IFL (irinotecan, 5-fluorouracil, and leucovorin) and FOLFOX (leucovorin, 5-fluorouracil, oxaliplatin) regimens significantly improved progression-free and overall survival [4, 5] . Furthermore, trials in other cancers including non-small cell lung cancer, renal cell cancer, and glioblastoma have shown that bevacizumab is significantly active in multiple tumor types [6] [7] [8] .
Infusion-related hypersensitivity reactions (HSRs) had been a potential concern with bevacizumab at the outset of clinical development secondary to the fact that bevacizumab is a monoclonal antibody containing up to 10% murine protein. It is likely that due to the experience with prior monoclonal antibodies (i.e. rituximab), the concern for HSRs was extrapolated to bevacizumab. All registrational and phase III trials of bevacizumab have infused intravenous bevacizumab according to the currently approved Food and Drug Administration (FDA) recommendation. The recommendation is that the first bevacizumab infusion should be given over 90 min, the second infusion over 60 min and all subsequent infusions should be given over 30 min if tolerated. Despite the theoretical concern that existed at the time of development, the incidence of clinically significant HSRs was exceedingly low for standard infusions of bevacizumab.
The standard infusion sequence was challenged in a study published by Reidy et al. at the Memorial Sloan-Kettering Cancer Center [9] . The goal of this retrospective study was to show that bevacizumab can be administered safely without initial prolonged infusion times. No HSRs were encountered when the infusion rate was modified to 30 min for all bevacizumab infusions. Further, when an additional 370 patients received 5 mg/kg dose of bevacizumab at an infusion rate of 0.5 mg/kg/min, only six (1.6%) experienced HSRs. None of the six patients experienced serious HSRs [9] . Therefore, this study suggested that bevacizumab over 0.5 mg/kg/min could be safely administered without increasing the risk of serious HSR, and that the precaution of the longer initial infusion times appeared to be unwarranted.
Shorter infusions of bevacizumab have not been adopted at many centers across the United States or by the FDA. This is likely due to the need for more safety data as well as concern of its impact on the other bevacizumab induced toxic effects. Bevacizumab can cause multiple serious toxic effects including proteinuria and hypertension. Multiple mechanisms behind bevacizumab-induced proteinuria and hypertension have been suggested, but the exact pathophysiology is not known [10] [11] [12] [13] . Although proteinuria is largely asymptomatic and low-grade, it can develop to nephrotic syndrome. Similarly, hypertension can result in hypertensive urgency or emergency. At this point, it is unclear whether a shorter duration infusion of bevacizumab increases the risk of proteinuria and hypertension.
Bevacizumab is commonly utilized to treat many patients with cancer. A better understanding of the safety of shorter infusions of bevacizumab would significantly improve patient care, convenience and productivity. It can help realize optimal health care utilization and significant cost avoidance. Therefore, the primary purpose of this study was to evaluate the incidence of proteinuria in patients receiving shorter infusions (0.5 mg/kg/min) of bevacizumab. The study also evaluated the incidence of hypertension as a secondary end point.
patients and methods
The eligible patients were those >18 years old receiving bevacizumab at a dose of <10 mg/kg. Patients were ineligible if they had received previous bevacizumab therapy. For the prospective arm of the study, patients were to receive bevacizumab infusion at 0.5 mg/kg/min. For the retrospective arm, patients had to have received bevacizumab infusion at a standard, FDA approved rate of administration to be eligible. The standard bevacizumab infusion consists of a first infusion over 90 min. The second infusion was over 60 min if the first infusion was tolerated. All subsequent infusions were over 30 min if the 60 min infusion was tolerated [14] .
This was a prospective, multi-center, observational study of patients receiving shorter, 0.5 mg/kg/min, infusions of bevacizumab. The results of the prospective study were compared with a historical control group of similar patients who received standard duration infusions of bevacizumab. The study was conducted at Veterans Affair North Texas Health Care System, Parkland Health and Hospital System, and Simmons Cancer Center in Dallas, Texas. The prospective and historical control arms study protocols were approved by the internal review boards of participating institutions. All patients provided written informed consent for the prospective arm of the study. The study was registered at clinicaltrials.gov (NCT00849394).
Patients were infused bevacizumab at 0.5 mg/kg/min for the prospective arm of the study. At baseline, before the first dose of bevacizumab, urine protein, serum creatinine and blood pressure were recorded. Subsequently, urine protein and serum creatinine were required, at minimum, every other cycle of bevacizumab. Blood pressure was taken before every cycle of bevacizumab. If anti-hypertensive medication was initiated during the study period, it was recorded. At baseline patient demographic data and pertinent past medical history, including hypertension, chronic kidney disease, diabetes mellitus and obesity, were collected. In addition, concomitant use of nephrotoxic, nephron-protective and anti-hypertensive medications was recorded. Cancer diagnosis and stage were verified through pathology reports and oncology clinical notes.
The study patients were followed until the onset of proteinuria that would warrant bevacizumab discontinuation or bevacizumab discontinuation due to progression, patient preference, or other serious toxicity. Proteinuria was measured by urinanalysis (UA) or urine dipstick. If patients presented with grade 2 (2+ or 100 to <300 mg/dL on urine dipstick) or higher proteinuria, 24 h urine protein or urine protein-tocreatinine (UPC) ratio was allowed at the discretion of the practitioner. This procedure was similar to the current standard of practice. All patients who received at least one dose of bevacizumab and had a urine protein evaluation after bevacizumab infusion were included in the analysis.
Patients for the historical control group were identified through either pharmacy or billing (J Code) records of bevacizumab. Patients were then screened for the eligibility. Demographic information including age, gender, weight, height, and chronic co-morbidities was collected. Patients' concurrent medications at baseline and any new anti-hypertensive during bevacizumab therapy were recorded. Pathology reports and hematology/ oncology clinical notes were reviewed for primary cancer diagnosis and initial staging. Data regarding chemotherapy regimens including date, dose infusion time, and schedule were collected for evaluation. The available proteinuria and blood pressure values were collected at baseline and throughout the bevacizumab therapies. Computerized and paper progress notes, chemotherapy orders and administration notes, and laboratory values were reviewed to collect the aforementioned data.
The primary end point of the study was incidence of proteinuria. Proteinuria was defined as ≥1+ on UA, ≥30 mg/dL protein on urine dipstick or ≥150 mg protein in 24 h urine collection or ≥300 mg/g UPC. In patients with baseline proteinuria, the incidence of proteinuria was considered only if the proteinuria worsened. The secondary end point of the study was incidence of hypertension. The grading of proteinuria and hypertension is provided in Table 1 . [15] [16] [17] [18] [19] A modified grading criterion was utilized for hypertension assessment due to the observational nature of the study design. The protocol initially called for 106 patients to be recruited in the study. This was based on 80% power and an alpha of 0.05 with expected proteinuria incidence of 42% in shorter compared with 24% results Sixty-five patients were enrolled in the prospective arm of the study. Two patients were excluded from the analysis. The first patient excluded was consented and did not receive any bevacizumab thereafter. The second patient excluded was hospitalized right after the first dose of bevacizumab due to severe toxicity and subsequently never received follow-up proteinuria analysis. A total of 63 patients (59 men and 4 women) received 392 shorter duration infusions of bevacizumab. The median age and weight of the patients were 62 years and 82 kg, respectively. Forty (63.5%) patients were either on anti-hypertensive medication or had a blood pressure >150/100 at baseline. The median blood pressure at baseline was 131/72 (Table 2 ). Fifteen (24%) patients had a past medical history of diabetes. Before the first dose of bevacizumab, 12 (19%) patients had pre-existing proteinuria. The majority of patients had colorectal cancer (92%) and received a 7.5 mg/kg dose (65%) of bevacizumab. There were three patients with the diagnosis of carcinoma of unknown primary. The median number of shorter infusions per patient was four (Table 3 ). All patients received concurrent 5-fluorouracil or capecitabine-based chemotherapy regimens with bevacizumab. Out of 63 patients, 19 (30.2%) experienced proteinuria on shorter infusions of bevacizumab. Thirteen (68%) had grade 1 proteinuria and six (32%) had grade 2. None of the patients experienced grade 3 or 4 proteinuria ( Table 4 ). The median time to proteinuria was 8 weeks and the median cumulative bevacizumab dose before the development of proteinuria was 15 mg/kg. Logistic regression analysis was negative for any confounding predictors of proteinuria development including The incidence of proteinuria and hypertension with shorter infusions of bevacizumab was then compared with the historical cohort that received standard duration infusions of bevacizumab. A total of 120 patients were eligible for the retrospective analysis. The majority of patients were male (77%), but they were statistically significantly less (P = 0.004) compared with patients receiving shorter infusions of bevacizumab (94%). Patient's age, weight, blood pressure and colorectal cancer diagnosis were similar between the two study arms at baseline. There were significantly less (60% versus. 43%; P = 0.02) patients receiving active hypertensive medications in the standard infusion arm. The majority of patients in the standard infusion arm received 5 mg/kg of bevacizumab (78%), compared with the shorter infusion arm (P < 0.001). Therefore, patients in standard infusion arms primarily received bevacizumab every 2 weeks and not every 3 weeks.
Forty-six (38.3%) out of 120 patients receiving standard infusions of bevacizumab developed proteinuria. Only 1 out of 46 patients had grade 3 proteinuria. The median cumulative dose of bevacizumab before the development of proteinuria was 21 mg/kg and the median time to proteinuria was 9 weeks. Overall, grade 1, grade 2 and grade 3/4 incidence of the proteinuria was statistically non-significant compared with shorter infusions of bevacizumab. Logistic regression analysis of patients in the standard infusion arm alone and together with the shorter infusion arm was negative for any confounding predictors of proteinuria including the 7.5 mg/kg bevacizumab, cumulative doses of bevacizumab, age or history of hypertension.
The incidence of hypertension was at 57% in patients receiving standard infusions of bevacizumab. There were 11 patients (9%) who experienced grade 4 hypertension (Table 4) . Logistic regression analysis was negative for bevacizumab dose as a predictor of hypertension in both the arms. Univariate regression analysis of the standard infusion arm of patients receiving more than four cycles of bevacizumab revealed a *Statistically significant at P < 0.001. Bev, bevacizumab. 
discussion
In this study, patients who received bevacizumab infusions at 0.5 mg/kg/min did not have an increased risk of proteinuria compared with standard infusions of bevacizumab. The overall incidence of hypertension was similar between the two study arms as well. To our knowledge, this is the first prospective study evaluating the incidence of proteinuria and hypertension in patients receiving shorter infusions of bevacizumab. The comparator retrospective arm provides the rate of incidence of proteinuria and hypertension with standard infusions of bevacizumab at the same institutions involved in the study. We chose to include patients receiving bevacizumab at a dose of <10 mg/kg only to assure a distinct infusion time difference between the two study arms (10-15 min versus at least 30 min infusions). Patients at the 15 mg/kg dose would receive bevacizumab infusions over 30 min, which is the same as a bevacizumab infusion over 0.5 mg/kg/min; therefore these patients were excluded. The incidence of proteinuria reported in our study is similar to what is reported in randomized phase III clinical trials where patients received standard infusions of bevacizumab. Patients who received shorter infusions of bevacizumab in our study had 30.2% incidence of overall proteinuria compared with 14%-38% reported in the randomized trials (Table 4) [4, 5, [20] [21] [22] [23] . The incidence of grade 3 or 4 proteinuria was similar as well. All patients in the selected randomized trials had colorectal cancer and received either 5 or 7.5 mg/kg of bevacizumab, which was the primary patient population in our study. Furthermore, we compared our result with these prospective, randomized trials as they had at least 200 study patients, and had reported the incidence of grade 3/4 proteinuria and hypertension (Table 4) .
A higher incidence of all grade and grade 4 hypertension was observed in this study with shorter infusions of bevacizumab than that reported in the randomized trials (Table 4) . Most of the patients in the randomized trials were excluded if they had clinically significant cardiovascular disease at baseline. These trials fail to report the incidence of hypertension at baseline or the number of patients on active anti-hypertensive medications as well. These randomized trials had a very select patient population and excluded patients with significant co-morbidities. The present study did not exclude patients based on co-morbidities. In addition, the definition of grade 4 hypertension in our study was more liberal than the standard definitions of grade 4 hypertension. This study assigned grade 4 hypertension only based on patient blood pressure and did not assess for the presence of clinical symptoms or progressive or impending target organ damage. Importantly, no significant difference in the incidence of hypertension was seen between the prospective cohort in this study who received a shorter infusion of bevacizumab and the retrospective cohort receiving standard infusions. This argues strongly that the impact of a shorter infusion on the incidence of hypertension is negligible when similar patient groups are compared and when identical grading scales are utilized.
The similar incidence of proteinuria and hypertension found between the shorter and standard infusion arms in this study suggests an insignificant impact of peak bevacizumab blood concentrations on toxicity. This study also suggested no correlation between the dose of bevacizumab and the risk of proteinuria. The logistic regression analysis failed to support an increased risk of proteinuria in patients receiving 7.5 mg/kg over 5 mg/kg doses of bevacizumab. In addition, proteinuria does not seem to be a cumulative toxicity of bevacizumab, since the standard deviation for the mean time and dose to proteinuria in both the arms of the study were wide. Furthermore, the logistic regression analysis failed to show any correlation between the cumulative doses of bevacizumab and the increased risk of proteinuria in the study.
In conclusion, the bevacizumab package insert recommended that a standard infusion rate of bevacizumab administration is unnecessary. A prior study has shown that a shorter infusion of bevacizumab does not increase the risk of infusion-related HSRs [9] . Our study further supports the safety of shorter infusions by suggesting that shorter infusions of bevacizumab do not increase the risks of proteinuria and hypertension. Therefore, we strongly support that 0.5 mg/kg/ min infusions of bevacizumab can be administered safely in patients with cancer. This finding is significant for community and academic cancer practices as bevacizumab is commonly utilized to treat many cancers including colorectal, lung, glioblastoma, renal cell and others. Adoption of shorter bevacizumab infusion rates can have a positive impact on resource utilization. Shorter bevacizumab infusions can result in a significant reduction in chemotherapy chair time and nursing workload, which can result in increased productivity for the patient and the cancer center. 
